Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443393 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAOBTSHRLMNACYP3A4 | |
| SCHEMBL19327561 | 0.82 | PYCR1 (0.45) | ALDH1A1MAOBTSHRPYCR1L3MBTL1 | |
| SCHEMBL17786046 | 0.82 | PYCR1 (0.45) | ALDH1A1MAOBMAOAPYCR1AOC3 | |
| SCHEMBL17786643 | 0.82 | PYCR1 (0.45) | ALDH1A1MAOBLMNAMAOAPYCR1 | |
| SCHEMBL5962473 | 0.82 | TSHR (0.54) | ALDH1A1MAOBTSHRLMNACYP3A4 | |
| SCHEMBL27785349 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAOBTSHRLMNACYP3A4 | |
| SCHEMBL11705199 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAOBTSHRLMNACYP3A4 | |
| SCHEMBL12562387 | 0.76 | TSHR (0.50) | ALDH1A1TSHRLMNAAOC3L3MBTL1 | |
| SCHEMBL10684904 | 0.75 | PYCR1 (0.66) | ALDH1A1MAOBTSHRLMNACYP3A4 | |
| SCHEMBL16889019 | 0.75 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNAAOC3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829453-B2 | Antagonists of the kappa opioid receptor | UNIVERSITY OF KANSAS (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190300486-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-10-03 | — | — | US | disclosed |
| US-10118896-B2 | Antagonists of the kappa opioid receptor | UNIVERSITY OF KANSAS (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170260141-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| WO-2016086149-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF KANSAS (US) | 2016-06-02 | — | — | WO | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | ALDH1A1 180/4885MAOB 1057/4885TSHR 4241/4885 |
| US-10829453-B2 | Antagonists of the kappa opioid receptor | OPRK1, OPRD1, OPRL1 | ALDH1A1 3883/4885MAOB 813/4885TSHR 357/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | ALDH1A1 600/4885MAOB 546/4885TSHR 2667/4885 |
| US-10118896-B2 | Antagonists of the kappa opioid receptor | OPRK1, OPRD1, OPRL1 | ALDH1A1 3883/4885MAOB 813/4885TSHR 357/4885 |
| US-20190300486-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | OPRK1, OPRD1, OPRL1 | ALDH1A1 3883/4885MAOB 813/4885TSHR 357/4885 |
| US-20170260141-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | OPRK1, OPRD1, OPRL1 | ALDH1A1 3883/4885MAOB 813/4885TSHR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.